Therapure Biopharma has announced today that its biomanufacturing division, Therapure Biomanufacturing, has won the 2013 CMO Leadership Award as a leader in all five categories: Quality, Reliability, Innovation, Productivity and Regulatory.

The CMO Leadership Award is based on the responses of more than 10,000 pharmaceutical and biopharmaceutical executives in a survey conducted by Nice Insight and presented by Life Science Leader Magazine.

The award recognizes contract manufacturing organizations that achieve customer perception scores in the top 20% in the five industry-driven categories.

In accepting the 2013 award, Therapure Biopharma president and chief executive officer Nick Green said: "It is an honor to be recognized for a third consecutive year for the CMO Leadership Award, and once again in all five categories. This award recognizes the diligence, passion and contribution of our employees who strive to meet our clients’ needs and produce the highest quality therapeutics possible. The five categories are critical to our clients’ success and more importantly for patient well being."

Theapure Biomanufacturing will be recognized as an award winner in the annual CMO Leadership Awards supplement published by Life Science Leader in October.

To meet the Therapure Contract Development and Manufacturing Organization (CDMO) team and discuss how they can help you with your biomanufacturing needs, they invite you to visit Therapure at the:

  • BioProcess International conference, Booth 906, 17-19 September, 2013, in Boston, MA
  • ContractPharma conference, Booth 10, 19 September 2013, in New Brunswick, NJ

Therapure Biopharma is also pleased to announce the launch of its new website. The new website, designed with a fresh new look and user-friendly navigation, reflects the unique business structure of the organization, which is comprised of Therapure Biomanufacturing the award-winning CDMO division, and Therapure Innovations the proprietary drug pipeline and platform technology research and development division.